Signals, Powered By EquityPandit
Jubilant Life Science has said that its wholly-owned subsidiary has got the Australian health regulator Therapeutic Goods Administration (TGA)’s approval for Lyophilized kit for preparation of injection that is used for lungs scan.
Jubilant Life Science has said in a BSE filing that “Jubilant Pharma, through one of its units Jubilant Draxlmage Inc Montreal Canada (JDI), has received approval from TGA, Australia, for Lyophilized kit for preparation of Technetium 99m Macro-Aggregated Albumin (MAA) injection.”
It has further said that “MAA provides accurate scans to assess lung perfusion and rule out pulmonary embolism with low radiation exposure. JDI is the leading supplier of MAA in the US and has approved in four other countries, including Canada, Columbia, Hong Kong and Israel.”
